Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations?
The therapeutic value of omega-3 polyunsaturated fatty acids (PUFAs), mainly (but not only) found in fish oils, eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), has been extensively studied in a wide variety of disease conditions, predominantly in cardiovascular disease. Howev...
Published in: | Expert Opinion on Pharmacotherapy |
---|---|
Main Authors: | , |
Other Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2015
|
Subjects: | |
Online Access: | http://hdl.handle.net/11585/522107 https://doi.org/10.1517/14656566.2015.991308 http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.991308 |
id |
ftunibolognairis:oai:cris.unibo.it:11585/522107 |
---|---|
record_format |
openpolar |
spelling |
ftunibolognairis:oai:cris.unibo.it:11585/522107 2023-09-05T13:16:05+02:00 Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? CICERO, ARRIGO FRANCESCO GIUSEPPE BORGHI, CLAUDIO Cicero, Af Borghi, C. 2015 STAMPA http://hdl.handle.net/11585/522107 https://doi.org/10.1517/14656566.2015.991308 http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.991308 eng eng info:eu-repo/semantics/altIdentifier/pmid/25474717 info:eu-repo/semantics/altIdentifier/wos/WOS:000348147200002 volume:16 issue:3 firstpage:285 lastpage:288 numberofpages:4 journal:EXPERT OPINION ON PHARMACOTHERAPY http://hdl.handle.net/11585/522107 doi:10.1517/14656566.2015.991308 info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84921481770 http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.991308 bioavailability docosahexaenoic acid eicosapentaenoic acid fish oil polyunsaturated fatty acid info:eu-repo/semantics/article 2015 ftunibolognairis https://doi.org/10.1517/14656566.2015.991308 2023-08-21T21:00:40Z The therapeutic value of omega-3 polyunsaturated fatty acids (PUFAs), mainly (but not only) found in fish oils, eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), has been extensively studied in a wide variety of disease conditions, predominantly in cardiovascular disease. However, the significant difference in efficacy observed in various conditions with different dosages seems to be at least partly related to the large discrepancy in quality of the product and to the bioavailability of the omega-3 PUFA. The research of new sources (e.g., from arctic Krill oil) and pharmaceutical forms of omega-3 PUFA (e.g., omega-3 carboxylic acids) is needed in order to detect the one with the best bioavailability and efficacy, and with a parallel reduction in the production costs. There is also the need to understand if long-term PUFA supplementation could increase the efficacy of the alreadyavailable evidence--based therapies for cardiovascular disease prevention and for the management of the diseases where the use of PUFA could have a possible improving effect. Article in Journal/Newspaper Arctic krill Arctic IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) Arctic Expert Opinion on Pharmacotherapy 16 3 285 288 |
institution |
Open Polar |
collection |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
op_collection_id |
ftunibolognairis |
language |
English |
topic |
bioavailability docosahexaenoic acid eicosapentaenoic acid fish oil polyunsaturated fatty acid |
spellingShingle |
bioavailability docosahexaenoic acid eicosapentaenoic acid fish oil polyunsaturated fatty acid CICERO, ARRIGO FRANCESCO GIUSEPPE BORGHI, CLAUDIO Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
topic_facet |
bioavailability docosahexaenoic acid eicosapentaenoic acid fish oil polyunsaturated fatty acid |
description |
The therapeutic value of omega-3 polyunsaturated fatty acids (PUFAs), mainly (but not only) found in fish oils, eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), has been extensively studied in a wide variety of disease conditions, predominantly in cardiovascular disease. However, the significant difference in efficacy observed in various conditions with different dosages seems to be at least partly related to the large discrepancy in quality of the product and to the bioavailability of the omega-3 PUFA. The research of new sources (e.g., from arctic Krill oil) and pharmaceutical forms of omega-3 PUFA (e.g., omega-3 carboxylic acids) is needed in order to detect the one with the best bioavailability and efficacy, and with a parallel reduction in the production costs. There is also the need to understand if long-term PUFA supplementation could increase the efficacy of the alreadyavailable evidence--based therapies for cardiovascular disease prevention and for the management of the diseases where the use of PUFA could have a possible improving effect. |
author2 |
Cicero, Af Borghi, C. |
format |
Article in Journal/Newspaper |
author |
CICERO, ARRIGO FRANCESCO GIUSEPPE BORGHI, CLAUDIO |
author_facet |
CICERO, ARRIGO FRANCESCO GIUSEPPE BORGHI, CLAUDIO |
author_sort |
CICERO, ARRIGO FRANCESCO GIUSEPPE |
title |
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
title_short |
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
title_full |
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
title_fullStr |
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
title_full_unstemmed |
Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
title_sort |
do we need ‘new’ omega-3 polyunsaturated fatty acids formulations? |
publishDate |
2015 |
url |
http://hdl.handle.net/11585/522107 https://doi.org/10.1517/14656566.2015.991308 http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.991308 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic krill Arctic |
genre_facet |
Arctic krill Arctic |
op_relation |
info:eu-repo/semantics/altIdentifier/pmid/25474717 info:eu-repo/semantics/altIdentifier/wos/WOS:000348147200002 volume:16 issue:3 firstpage:285 lastpage:288 numberofpages:4 journal:EXPERT OPINION ON PHARMACOTHERAPY http://hdl.handle.net/11585/522107 doi:10.1517/14656566.2015.991308 info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84921481770 http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.991308 |
op_doi |
https://doi.org/10.1517/14656566.2015.991308 |
container_title |
Expert Opinion on Pharmacotherapy |
container_volume |
16 |
container_issue |
3 |
container_start_page |
285 |
op_container_end_page |
288 |
_version_ |
1776197807394258944 |